Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
(Thomson Reuters ONE) -
Novartis International AG /
Novartis Foundation showcases progress in leprosy elimination programs at 19th
International Leprosy Congress
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Emerging evidence from first 18 months of LPEP program demonstrates
operational feasibility integrating single-dose rifampicin into routine
control programs in 6 countries
* Retrospective contact tracing of former leprosy patients in Cambodia
initiates phase 2 to accelerate diagnosis
* Accuracy of first mobile phone-facilitated leprosy detection system to help
identify patients in remote areas of the Philippines leads to recommendation
for field use
* Criteria for development of a molecular diagnostic test for leprosy
determined
The digital press release with multimedia content can be accessed here:
Basel, September 15, 2016 - The Novartis Foundation and its partners will
highlight progress in efforts toward accelerating the elimination of leprosy at
the 19(th) International Leprosy Congress (ILC) held in Beijing, China from
September 18 - 21, 2016. Updates in 11 abstracts on four Novartis Foundation-
supported leprosy initiatives in low- and middle-income countries will be
showcased in scientific sessions.
Abstracts presented at the ILC demonstrate progress on the key programs under
the Novartis Foundation strategy toward zero transmission of leprosy. The
strategy was launched in 2014 to prioritize early detection and treatment,
contact tracing and preventative treatment, strengthening of surveillance
systems to become action-oriented and developing tools for faster and earlier
diagnosis.
"The ILC is a great opportunity to present results of our leprosy strategy
gaining momentum, share learnings, and highlight the research we support on
diagnostic development and epidemiological modelling, which can contribute to
the design of future strategies to finally make leprosy history. I am
particularly pleased to share emerging evidence on our multi-country Leprosy
Post-Exposure Prophylaxis (LPEP) program, which at mid-point is already
demonstrating the feasibility of integrating its strategy of contact tracing and
preventative therapy in national control programs," said Dr. Ann Aerts, Head of
the Novartis Foundation.
Novartis Foundation-sponsored projects presented at ILC scientific sessions:
* Cambodia Retrospective Active Case Finding project: recommendations for
targeting high-priority districts in phase 2 (Abstract ILC4.2-052/8.5,
September 19, 13:30 CST)
* Accuracy of the Leprosy Alert Response Network and Surveillance (LEARNS)
System of the Novartis Foundation and Philippine Department of Health -
National Leprosy Control Program (ILC4.2-025/8.3, September 19, 13:30 CST)
* Criteria for a developing a PCR test (Abstract 47.1, September 20, 10:30
CST)
* Emerging evidence from the Leprosy Post-Exposure Prophylaxis project
(Abstract ILC4.3-012/17.1, September 20, 13:30 CST)
* An interim report on the operational feasibility of leprosy post-exposure
prophylaxis in Dadra and Nagar Haveli, India (Abstract ILC4.3-014/17.2,
September 20, 13:30 CST)
* Comparison of implementation aspects of Leprosy Post-Exposure Prophylaxis in
India, Nepal and Indonesia (Abstract ILC4.3-022/17.3, September 20, 13:30
CST)
* Negotiating and implementing the Leprosy Post-Exposure Prophylaxis project
in the centralized health service of the Union of Myanmar (Abstract ILC4.3-
011/17.4, September 20, 13:30 CST)
* LPEP and implementation experiences from Nepal (Abstract ILC4.3-009/17.5,
September 20, 13:30 CST)
* Modeling the long term impact of additional interventions on the new case
detection rate of leprosy in three endemic countries and regions (Abstract
ILC4.3-007/17.6, September 20, 13:30 CST)
* Delivering leprosy post-exposure prophylaxis in a remote area: a case of
Lingat Village, Maluku, Indonesia (Abstract ILC4.3-017/25.6, September
20, 15:30 CST)
* Distribution of leprosy post-exposure prophylaxis through extended contact-
tracing with self-screening approach in Sumenep District, Indonesia
(Abstract ILC4.3-018/25.8, September 20, 15:30 CST)
"This year we commemorate 30 years of Novartis Foundation commitment in the
fight against leprosy," reflected Ann Aerts; "therefore the ILC is timely to
review the progress we are making together with our partners toward zero
transmission of leprosy. It is also a fitting time to look ahead and envision a
coalition to bring the anti-leprosy community together to go the last mile in
the fight against leprosy."
Novartis and the Novartis Foundation have a long-term commitment to leprosy
treatment and control. Since 2000, Novartis has donated more than 56 million
blister packs valued at approximately USD 90 million through the World Health
Organization (WHO), helping to treat more than six million leprosy patients
worldwide.
Disclaimer
This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as "emerging,"
"recommendation," "initiatives," "will," "strategy," "can," "strategies,"
"commitment," "look ahead," "envision," "long-term," or similar expressions.
Such forward-looking statements reflect the current views of the Group regarding
future events, and involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from any future
results expressed or implied by such statements. These expectations could be
affected by, among other things, risks and factors referred to in the Risk
Factors section of Novartis AG's current Form 20-F on file with the US
Securities and Exchange Commission. Novartis is providing the information in
this press release as of this date and does not undertake any obligation to
update it in the future.
About the Novartis Foundation
The Novartis Foundation is a philanthropic organization pioneering innovative
healthcare models that can have a transformational impact on the health of the
poorest populations. We work hand-in-hand with our local and global partners to
catalyze scalable and sustainable healthcare models to improve access and health
outcomes, and to accelerate efforts to eliminate leprosy and malaria by focusing
on interventions that aim to interrupt transmission. Everything we do is
grounded in evidence and innovation, and our work is a continuous cycle of
evaluation, adaptation and application. In 2015, the operational budget for the
foundation was CHF 12 million and our programs reached 4.5 million people.
For more information, please visit:
www.novartisfoundation.org
www.youtube.com/novartisfoundation
Novartis Foundation is on Twitter. Sign up to follow (at)NovartisFDN at
https://twitter.com/NovartisFDN
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2015, the Group achieved net
sales of USD 49.4 billion, while R&D throughout the Group amounted to
approximately USD 8.9 billion (USD 8.7 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 118,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Patrick Barth Kiara Barnes
Novartis Global Media Relations Novartis Foundation
+41 61 696 6273 (direct) +41 61 696 8181 (direct)
+41 79 732 0801 (mobile) +41 79 724 7037 (mobile)
patrick.barth(at)novartis.com kiara.barnes(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Sloan Pavsner +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2042257/762244.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Endeavour Silver Signs Agreement to Acquire Exploration Properties in Parral District, Chihuahua, Mexico from Silver StandardDatum: 15.09.2016 - 07:15 Uhr
Sprache: Deutsch
News-ID 494888
Anzahl Zeichen: 10413
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 268 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
